Sertificate of Registration GMP/LE/2004/002 Sertificate of Registration ISO 9001:2000 Sertificate of Registration ISO 9001:2000
Choose
your language:
English Russian
Choose the firm:
 Registrations
 Our partners
 Contact Us
 Search
 Price
For registered users
login
password
    
featured products
    Glucose 5%
    Cipro-Tech
    Iono-Tech
    Manni-Tech 10%
    Metronidazole 0.5%
    NaCl 0.9%
    Rheopolyglucinum
    Ringer
    Solutio Novocaini 0.25%
    Natrii citrati 4%
    Diprosalic Lotion 30 ml
    Freederm Shampoo Tar 150 ml
    Intron 18 miu 3ml 1 vial
    Triderm Cream 15 g
    Augmentin tab. 375mg N20
    Augmentin inj. 600mg N1
    Dermovate Oint 25g Tube
    Imigran Tab. 50mg N2
    Levitra 5mg 2 tab
    Mylogin Caps 250mg N10
    Mylogin Caps 250mg N20
    Oxybral Caps 30mg N20
    Septrin Paed Susp 100ml N1
    Valtrex tab. 500mg N10
    Vitamax Caps N5
    Zantac Tab. 150mg N20
    Zeffix Tab 100mgx28
    Zinacef Inj 750mg N1
    Zofran Tab 4mg N10
    Zyban 150 mg tabs. X 60
    Wellbutrin SR 150mg 60 tab
    Astmopent Aer 400Ds 0.75mg
    Salbutamol inh
information about product

POTASSIUM CLORIDE INJECTIONS
(Intravenous solution)

The trading (patented) name of a preparation - KCl 4% FOR INJECTIONS
The international name - Potassium Chloride For Injections
ATC-CODE - A12BA01

ACTIVE COMPONENTS
potassium chloride

DESCRIPTION
Colorless transparent liquid

STRUCTURE AND THE FORM OF RELEASE
1 litre of a solution contains
Potassium chloride ............ 40 g
Other components: water for injection.
100, 200 ml of solution in plastic PVC containers.

PHARMACOLOGICAL GROUPE
Potassium preparations.

PHARMACOLOGICAL EFFECT
Potassium is the major intracellular ion. Reduces the stimulation of myocarditis, being the antagonist of cardiac glycosides in effecting the rhythm of heart, it holds their favourable inotropic effect. Potassium intake exceeds the acetylcholine contents and stimulation of sympathetic system; during administration of potassium stimulation of adrenal glands with the increased allocation of adrenaline is registered. The preparation enhances muscular pressing during muscular dystrophia, myasthenia.
Pharmcokinetics. Absorbed good and quickly, removed through kidneys.

INDICATIONS FOR ADMINISTRATION

- hyperkalemia or non metabolic alkalosis;
- intoxication with foxglove preparations;
- prevention of hyperkalemia in patients with arrhythmic heart or patients who received foxglove preparations;
- electrolyte balance disorder during liver cyrosis, accompanied by ascite during nefropathy, and heavy diarrhoea.

DOSAGE
Administered intravenously with controlled rate (20 30 drop/min.) up to 2,5 gr in the isotonic solution of sodium chloride 500 ml or in glucose 5 % solution.

OVERDOSAGE
Hyperkalemia (6,5 - 8,0 mEq/liter), first symptoms include ECG changes (peaking of -waves, loss of P-waves, depression of S-T Segment and prolongation of the QT interval) . Late manifestations include (9 - 12 mEq/liter): muscle paralysis and cardiovascular collapse from cardiac arrest. Paresthesia (first sign).

SIDE-EFFECTS
Intestines: nausea, vomiting, diarrhea, abdominal spasm/discomfort. Other: pain, thrombosis or phlebitis extending from the site of intravenous injection.

CONTRAINDICATION
Hyperkalemia, hypochloremia (hypochloremic alkolosis), renal failure, cardiac arrest.

MEDICINAL INTERACTION
The concomitant administration of potassium salts and potassium-sparing diuretic (e.g. spironolactone, triamterene or amiloride), non-steroid anti-inflammatory means can produce severe hyerkalemia and cardiac arrhythmia.

SPECIAL INDICATIONS
Should be administred intravenously only with controlled rate because of the higher risk of hyperkalemia, mostly in patients with renal insufficiency. Symptoms include: Paresthesias of extremities, weakness and heaviness of the legs, flaccid paralysis, heart block.
Potassium should be used with caution in patients having acute dehydration or extensive tissue breakdawn caused by severe burns.
Prolonged parenteral therapy requires careful attention to the serum electrolyte concentration levels and the ECG.
During potassium chloride conductivity deficiency it should be used with caution.

STORAGE CONDITIONS AND SHELF LIFE
The preparation must be stored in a dark place protected from light in regular conditions. Expiry date of the intravenous solution - 2 years.

  Copyright © 2006 PharmaTech